Two years before that, Huang et al. reported similar results in that both the frequency and absolute number of CD14+HLA-DR−/low cells were significantly increased in the peripheral blood of NSCLC patients and indicated an association with metastasis, response to chemotherapy, and progression-free survival [42]. The gene discussed is CD14; the disease is non-small cell lung carcinoma.